Possible interaction between aminophylline and ascorbic acid.

Acocella, G. (1978). Clinical pharmacokinetics of rifampicin. Clin. Pharmacokin., 3, 108-127. Binda, G., Domenichini, E., Gottardi, A., Orlandi, B., Ortelli, E., Pacini, B. & Fowst, G. (1971). Rifampicin, a general review. Arzneim-Forsch., 21, 1907-1977. Conney, A. H. (1967). Pharmacological implications of microsomal induction. Pharmac. Rev., 19, 317366. Das, K. M. & Dubin, R. (1976). Clinical pharmacokinetics of sulphasalazine. Clin. Pharmacokin., 1, 406-425. Hansson, N. A. & Sandberg, M. (1973). Determination of sulphasalazine and its metabolites in biological material after administration of sulphasalazine. Acta Pharm. Suec., 10, 87-92. Houston, J. B., Day, S. & Walker, J. (1982). Azo reduction of sulphasalazine in healthy volunteers. Br. J. clin. Pharmac., 14, 395-398. Klotz, V., Maier, K., Fischer, C. & Heinkel, K. (1980). Therapeutic efficacy of sulphasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. New Engl. J. Med., 303, 1499-1502. Shaffer, J. L., Hughes, S., Linaker, B. D. & Turnberg, L. A. (1984). A controlled trial of rifampicin and ethambutol in Crohn's disease. Gut, 25, 203-205. Schroder, H., Lewkonia, R. M. & Price Evans, D. A. (1973). Metabolism of salicylazosulphapyridine in healthy subjects and in patients with ulcerative colitis. Clin. Pharmac. Ther., 14, 802-809. Van Hies, P. A. M., Bakker, J. H. & van Tongereun, J. H. M. (1980). Effect of sulphapyridine, 5aminosalicylate and placebo in patients with idiopathic proctitis: A study to determine the active therapeutic moiety of sulphasalazine. Gut, 21, 632-635. Zilly, W., Breimer, D. D. & Richter, E. (1977). Pharmacokinetic interactions with rifampicin. Clin. Pharmacokin., 2, 61-70.